Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.

Franceschino, A., Tornaghi, L., Benemacher, V., Assouline, S., GAMBACORTI PASSERINI, C. (2008). Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. HAEMATOLOGICA, 93(2), 317-318 [10.3324/haematol.11680].

Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib

FRANCESCHINO, ANNA;GAMBACORTI PASSERINI, CARLO
2008

Abstract

Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.
Articolo in rivista - Articolo scientifico
imatinib, cml, ck, phophate, lipid
English
2008
93
2
317
318
none
Franceschino, A., Tornaghi, L., Benemacher, V., Assouline, S., GAMBACORTI PASSERINI, C. (2008). Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. HAEMATOLOGICA, 93(2), 317-318 [10.3324/haematol.11680].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/552
Citazioni
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 17
Social impact